Drugs / alum adjuvant
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00004184 | Aug 1998 → Jun 2001 | cutaneous melanoma | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00031733 | Feb 2002 → Dec 2004 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00007826 Background | Apr 2000 → ? | colorectal cancer | Onyvax | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alum adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00031733 ↗ |
| Route | Subcutaneous | “4B5 plus alum SQ on days 0, 14, 28, and 42” NCT00004184 ↗ |